1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shandong Wit Dyne Health Co., Ltd. Class A

Shandong Wit Dyne Health Co., Ltd. Class A

SSZSE:000915
24.18
CNY
-0.03
(-0.12%)
4.08EPS
13.13P/E
6.63BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.67
5.88
5.29
6.62
7.56
6.47
7.67
7.77
8.64
10
10.61
9.11
9.5
8.65
Basic EPS, GAAP
0.65
0.93
0.65
0.85
1.04
0.55
0.87
1.24
1.62
2.25
2.5
2.2
2.28
2.16
Free Cash Flow per Basic Share
0.64
0.82
0.9
1.16
1.06
1.73
0.3
2.7
2.71
4.73
4.8
3.78
5.21
- -
Dividend per Share
0.11
0.11
0.09
0.09
0.12
0.22
0.31
0.28
0.45
0.8
0.8
2.5
2.5
0.5
Book Value per Share
3.28
4.13
4.7
5.48
6.4
6.82
7.39
8.33
9.58
11.03
12.73
12.43
12.21
11.16
Tangible Book Value per Share
2.48
3.34
3.82
4.63
5.82
5.91
6.48
7.52
8.7
10.15
11.87
11.61
11.31
10.28
Basic Weighted Avg Shares
234
234
233
233
234
236
235
234
235
234
234
234
235
235
Sales/Revenue/Turnover
1,095
1,374
1,233
1,545
1,767
1,526
1,800
1,821
2,027
2,341
2,484
2,134
2,228
2,028
Operating Margin (%)
33.83
32.02
28.42
27.69
30.39
19.77
22.51
32.55
38.2
48.75
51.27
54.64
53.55
54.12
Depreciation Expense
29
35
36
41
43
48
57
65
69
68
73
73
71
- -
Net Income, GAAP
153
217
152
198
243
130
204
291
380
527
585
516
535
506
Effective Tax Rate (%)
14.05
13.98
13.99
13.63
14.29
11.24
13.36
13.27
14.23
13.92
14.96
14.61
14.78
14.32
Profit Margin (%)
13.99
15.82
12.36
12.84
13.76
8.5
11.34
15.97
18.76
22.51
23.56
24.16
24.01
24.92
Working Capital
397
658
654
786
922
1,133
1,258
1,618
1,967
2,630
3,112
3,093
3,076
2,528
LT Debt
32
3
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1,160
1,482
1,680
1,949
2,219
2,341
2,567
2,935
3,399
4,061
4,497
4,412
4,351
3,781
Return on Invested Capital (%)
23.29
23.7
15.04
18.3
21.05
10.37
14.56
19.3
22.11
26.54
25.99
22.09
22.81
23.33
Return on Capital (%)
3.52
3.97
3.03
2.57
1.74
0.91
2.03
1.78
1.78
1.5
1.02
0.56
0.95
1.33
Return on Common Equity (%)
21.87
25.05
14.73
16.63
17.47
8.37
12.26
15.79
18.12
21.82
21.03
17.5
18.54
17.71

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
234
234
234
Market Capitalization
7,742
7,309
6,634

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,627
3,589
2,797
Cash, Cash Equivalents & STI
3,264
3,263
2,205
Accounts Receivable, Net
67
119
376
Inventories
78
98
99
Total Current Liabilities
551
298
268
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.21%
8.55%
-1.4%
Free Cash Flow
88.71%
18.57%
38.06%
Net Income, GAAP
17.82%
14.46%
3.78%
Sales/Revenue/Turnover
6.84%
4.65%
4.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
572
583
224
757
2,134
2025
616
554
- -
626
2,228
2026
412
436
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.72
0.7
0.14
0.64
2.2
2025
0.78
0.66
- -
0.54
2.28
2026
0.47
0.48
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.5
- -
2.5
2025
- -
- -
- -
0.5
2.5
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jie Yang
Full Time Employees
1,719
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Huatai Plaza, No. 17703 Jinan SD China 250061
IPO Date
Jun 9, 1999
Website
sd-wit.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shandong Wit Dyne Health Co.,Ltd. Shandong Wit Dyne Health Co.,Ltd. (000915.SZ) engages primarily in the research, development, production and sales of children's medicines and health products in China. The company offers a broad portfolio of pharmaceutical and nutritional products including iquesin, dexin, dyne iron, dyne calcium, dyne zinc, pediatric ibuprofen suppositories, oral rehydration solution (III), dimercaptan capsules, tomoxetine hydrochloride oral solution, desloratadine oral solution, simethicone emulsion, sodium valproate oral solution, azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, dextran iron granules, rifaximin dry suspension, DHA series (DHA, DHA+ARA, DHA+PS), probiotic powder series, minerals soft gel series (calcium D, zinc, iron), oral liquid series (various minerals, calcium and zinc), chewable tablet series (multivitamin, calcium DK) and recombinant collagen gel/ointment dressing products; it also provides environmental protection solutions such as chlorine dioxide equipment, flue gas desulfurization services and wastewater treatment through subsidiaries. Founded in 1993 and headquartered in Jinan, Shandong Province, the company operates mainly in the domestic Chinese market with approximately 1,759 employees and targets pediatric healthcare segments including antibiotics, supplements, digestive aids and chronic condition treatments. In recent developments, a subsidiary obtained exclusive general distribution rights for Manlejing under the Noble Ren brand as of 2024, and the company changed its Chinese name to Shandong Huatai Dyne Health Co., Ltd. in April 2021 to reflect its focus on child health; it continues to emphasize innovation in pediatric medicines while maintaining environmental operations.